Colorectal Cancer Clinical Trials in New York

Showing 101-120 of 332 trials

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

NCT06040541

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Revolution Medicines, Inc.604 participantsStarted Sep 2023

Sacramento, California, United States • New Haven, Connecticut, United States • Sarasota, Florida, United States +14 more locations

RECRUITINGPhase 2< 1 mile

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

NCT05024097

Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.

Rectal Cancer

Weill Medical College of Cornell University43 participantsStarted Mar 2022

New York, New York, United States • New York, New York, United States • New York, New York, United States

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.

Colorectal Cancer Trials in Other Cities

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer

Blood and Stool Sample Collection in Subjects With a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

A Study to Investigate LYL845 in Adults With Solid Tumors

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

ColoCare Study - Colorectal Cancer Cohort

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Predicting Local and Distant Recurrence in T1 Colorectal Cancer

Stage II/III Colorectal Cancer Recurrence

Other Conditions in New York